A Phase 1 interventional study of LY3502970 in Healthy and Hepatic Insufficiency, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hepatic Insufficiency by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Hepatic Insufficiency · Eli Lilly and Company.
Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, this one is the 10th largest by enrollment, is one of 2 that started in 2023, is one of 12 in phase 1, and was the 7th registered.
113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.
Browse Hepatic Insufficiency studies →2 of the 12 studies in Hepatic Insufficiency by Eli Lilly and Company are open now, in 4 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Hungary
Ages 18–85 · Healthy volunteers
Eli Lilly and Company · Sites in Hungary, New Zealand, Slovakia
Ages 18–85 · Healthy volunteers
By country, each count listing its studies:
Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is close to the median of 29 across 100 interventional studies indexed under Hepatic Insufficiency.
Median enrollment 34 across the 12 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
2 of the studies in Hepatic Insufficiency by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07165002Eli Lilly and CompanyA Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment | 2026-11 |
| NCT07401862Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of LY3502970 will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with normal hepatic function received a single 1 milligram (mg) dose of LY3502970 administered orally on Day 1.
Drug: LY3502970
Participants with mild hepatic impairment received a single 1 mg dose of LY3502970 administered orally on Day 1.
Drug: LY3502970
Participants with moderate hepatic impairment received a single 1 mg dose of LY3502970 administered orally on Day 1.
Drug: LY3502970
Participants with severe hepatic impairment received a single 1 mg dose of LY3502970 administered orally on Day 1.
Drug: LY3502970
Administered orally.
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of LY3502970
PK: AUC (0-∞) of LY3502970.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1
PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY3502970
PK: AUC0-tlast of LY3502970.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1
PK: Maximum Observed Concentration (Cmax) of LY3502970
PK: Cmax of LY3502970.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1
| Milestone | 1 mg LY3502970 (Control: Normal Hepatic Function) | 1 mg LY3502970 (Mild Hepatic Impairment) | 1 mg LY3502970 (Moderate Hepatic Impairment) | 1 mg LY3502970 (Severe Hepatic Impairment) |
|---|---|---|---|---|
| Started | 11 | 6 | 6 | 6 |
| Received at least one dose of ly3502970 | 11 | 6 | 6 | 6 |
| Completed | 11 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
PK: AUC (0-∞) of LY3502970.
| nanogram *hour per milliliter (ng*h/mL) | 1 mg LY3502970 (Control: Normal Hepatic Function) | 1 mg LY3502970 (Mild Hepatic Impairment) | 1 mg LY3502970 (Moderate Hepatic Impairment) | 1 mg LY3502970 (Severe Hepatic Impairment) |
|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of LY3502970 | 130 ± 26.8 | 132 ± 60.2 | 209 ± 32.6 | 611 ± 84.6 |
PK: AUC0-tlast of LY3502970.
| ng*h/mL | 1 mg LY3502970 (Control: Normal Hepatic Function) | 1 mg LY3502970 (Mild Hepatic Impairment) | 1 mg LY3502970 (Moderate Hepatic Impairment) | 1 mg LY3502970 (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY3502970 | 109 ± 29.1 | 112 ± 64.0 | 169 ± 32.7 | 385 ± 54.7 |
PK: Cmax of LY3502970.
| nanograms per milliliter (ng/mL) | 1 mg LY3502970 (Control: Normal Hepatic Function) | 1 mg LY3502970 (Mild Hepatic Impairment) | 1 mg LY3502970 (Moderate Hepatic Impairment) | 1 mg LY3502970 (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of LY3502970 | 5.10 ± 21.0 | 5.47 ± 57.5 | 6.12 ± 43.6 | 5.95 ± 36.1 |
Collected over Baseline up to end of follow-up (up to 14 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1 mg LY3502970 (Control: Normal Hepatic Function) | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| 1 mg LY3502970 (Mild Hepatic Impairment) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 1 mg LY3502970 (Moderate Hepatic Impairment) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 1 mg LY3502970 (Severe Hepatic Impairment) | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Event | 1 mg LY3502970 (Control: Normal Hepatic Function) | 1 mg LY3502970 (Mild Hepatic Impairment) | 1 mg LY3502970 (Moderate Hepatic Impairment) | 1 mg LY3502970 (Severe Hepatic Impairment) |
|---|---|---|---|---|
| Abdominal discomfortGastrointestinal disorders | 1/11 | 0/6 | 1/6 | 0/6 |
| PruritusSkin and subcutaneous tissue disorders | 0/11 | 1/6 | 0/6 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 1/11 | 0/6 | 0/6 | 0/6 |
| HeadacheNervous system disorders | 1/11 | 0/6 | 0/6 | 0/6 |
All enrolled participants.
| Age, Continuous(years) | 1 mg LY3502970 (Control: Normal Hepatic Function) | 1 mg LY3502970 (Mild Hepatic Impairment) | 1 mg LY3502970 (Moderate Hepatic Impairment) | 1 mg LY3502970 (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| Mean | 54.1 ± 11.2 | 58.8 ± 14.6 | 64.3 ± 5.5 | 47.5 ± 6.8 | 55.8 ± 11.4 |
| Sex: Female, Male(Participants) | 1 mg LY3502970 (Control: Normal Hepatic Function) | 1 mg LY3502970 (Mild Hepatic Impairment) | 1 mg LY3502970 (Moderate Hepatic Impairment) | 1 mg LY3502970 (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| Female | 4 | 3 | 1 | 4 | 12 |
| Male | 7 | 3 | 5 | 2 | 17 |
| Ethnicity (NIH/OMB)(Participants) | 1 mg LY3502970 (Control: Normal Hepatic Function) | 1 mg LY3502970 (Mild Hepatic Impairment) | 1 mg LY3502970 (Moderate Hepatic Impairment) | 1 mg LY3502970 (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 3 | 4 | 4 | 18 |
| Not Hispanic or Latino | 4 | 3 | 2 | 2 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 1 mg LY3502970 (Control: Normal Hepatic Function) | 1 mg LY3502970 (Mild Hepatic Impairment) | 1 mg LY3502970 (Moderate Hepatic Impairment) | 1 mg LY3502970 (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 0 | 0 | 2 |
| White | 8 | 5 | 6 | 6 | 25 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | 1 mg LY3502970 (Control: Normal Hepatic Function) | 1 mg LY3502970 (Mild Hepatic Impairment) | 1 mg LY3502970 (Moderate Hepatic Impairment) | 1 mg LY3502970 (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| United States | 11 | 6 | 6 | 6 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2023 to primary completion in Nov 2024, 17 months.
Results were first posted in May 2026, 1 year 6 months after primary completion.
Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 17 months is above that.
Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron